Biomarker-driven patient stratification

Our biomarkers enable precise identification of responders and non-responders, facilitating patient enrichment strategies and maximizing clinical trial efficacy

De-risking drug development

By integrating robust diagnostic markers into clinical studies, pharma partners can improve endpoint accuracy, reduce trial costs, and accelerate regulatory approval.

Supporting precision medicine

SphingoTec’s solutions help bridge the gap between diagnostics and therapeutics, paving the way for personalized approaches in critical care.